Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 9,200 shares of the business's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total value of $98,808.00. Following the completion of the sale, the insider now owns 320,647 shares in the company, valued at $3,443,748.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Los Pinos Elisabet De also recently made the following trade(s):
- On Friday, October 18th, Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68.
Aura Biosciences Stock Down 2.5 %
Shares of AURA stock traded down $0.27 on Tuesday, reaching $10.71. The stock had a trading volume of 109,945 shares, compared to its average volume of 176,213. Aura Biosciences, Inc. has a 12 month low of $5.99 and a 12 month high of $12.38. The firm has a market capitalization of $530.61 million, a price-to-earnings ratio of -5.76 and a beta of 0.37. The firm's 50-day moving average is $9.05 and its two-hundred day moving average is $8.23.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. On average, sell-side analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aura Biosciences
A number of large investors have recently added to or reduced their stakes in AURA. Regency Capital Management Inc. DE grew its stake in Aura Biosciences by 11.4% in the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company's stock valued at $6,163,000 after buying an additional 80,162 shares during the last quarter. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company's stock worth $138,000 after acquiring an additional 3,782 shares during the period. Levin Capital Strategies L.P. grew its position in shares of Aura Biosciences by 11.2% in the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company's stock valued at $873,000 after purchasing an additional 11,200 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Aura Biosciences during the first quarter worth approximately $144,000. Finally, Bank of New York Mellon Corp boosted its stake in Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company's stock valued at $1,081,000 after purchasing an additional 48,549 shares during the period. Institutional investors own 96.75% of the company's stock.
Wall Street Analyst Weigh In
AURA has been the subject of several recent research reports. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a report on Monday, September 9th. Evercore ISI upgraded shares of Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 16th. Cowen reaffirmed a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. HC Wainwright increased their price target on Aura Biosciences from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Finally, BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Aura Biosciences currently has a consensus rating of "Buy" and an average target price of $23.00.
View Our Latest Report on AURA
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
